Risk Group-Adapted Adjuvant Radiotherapy for WHO Grade I and II Skull Base Meningioma

Apr 5, 2019·

Sangjoon Park

,

Yoon Jin Cha

,

Sang Hyun Suh

,

Ik Jae Lee

,

Kyu-Sung Lee

,

Chang-Ki Hong✉

,

Jun Won Kim✉

· 0 min read

Publication

Journal of Cancer Research and Clinical Oncology, 145, 1351-1360

Last updated on Mar 8, 2025

← Acute Severe Lymphopenia by Radiotherapy is Associated with Reduced Overall Survival in Hepatocellular Carcinoma Apr 15, 2019

Clinical Significance of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Hepatocellular Carcinoma Patients Treated with Radiotherapy Oct 1, 2018 →